Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 13.08 -2.97% -0.40
FATE closed down 2.97 percent on Thursday, June 21, 2018, on 83 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical FATE trend table...

Date Alert Name Type % Chg
Jun 21 Stochastic Reached Overbought Strength 0.00%
Jun 21 Upper Bollinger Band Walk Strength 0.00%
Jun 21 Above Upper BB Strength 0.00%
Jun 21 Overbought Stochastic Strength 0.00%
Jun 21 Upper Bollinger Band Touch Strength 0.00%
Jun 20 BB Squeeze Ended Range Expansion -2.97%
Jun 20 Above Upper BB Strength -2.97%
Jun 20 Gapped Up Strength -2.97%
Jun 20 Upper Bollinger Band Touch Strength -2.97%
Jun 19 Bollinger Band Squeeze Range Contraction 6.26%

Older signals for FATE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.45
52 Week Low 2.52
Average Volume 638,695
200-Day Moving Average 7.8692
50-Day Moving Average 11.0858
20-Day Moving Average 11.653
10-Day Moving Average 12.074
Average True Range 0.8694
ADX 24.53
+DI 38.21
-DI 9.53
Chandelier Exit (Long, 3 ATRs ) 11.2418
Chandelier Exit (Short, 3 ATRs ) 12.6182
Upper Bollinger Band 12.9903
Lower Bollinger Band 10.3157
Percent B (%b) 1.03
BandWidth 22.95203
MACD Line 0.4952
MACD Signal Line 0.3362
MACD Histogram 0.159
Fundamentals Value
Market Cap 541.7 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -13.63
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.83
Resistance 3 (R3) 14.89 14.37 14.54
Resistance 2 (R2) 14.37 13.92 14.34 14.44
Resistance 1 (R1) 13.73 13.65 13.47 13.66 14.34
Pivot Point 13.21 13.21 13.08 13.17 13.21
Support 1 (S1) 12.56 12.76 12.30 12.50 11.82
Support 2 (S2) 12.04 12.49 12.01 11.72
Support 3 (S3) 11.40 12.04 11.62
Support 4 (S4) 11.33